Probiotics and nutraceuticals: Non-medicinal treatments of gastrointestinal diseases

Current Opinion in Pharmacology

Volumn 5, Issue 6 SPEC. ISS., 2005, Pages 596-603

  Penner, Robert ^a   Fedorak, Richard N ^a   Madsen, Karen L ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIMEL; AEGLE MARMELOES EXTRACT; ALPHA TOCOPHEROL; AMOXICILLIN; ANTIBIOTIC AGENT; ASCORBIC ACID; CODEX; CORIANDRUM SATIVUM EXTRACT; CURCUMA LONGA EXTRACT; CYPERUS ROTUNDUS EXTRACT; DOCOSAHEXAENOIC ACID; FISH OIL; FRUCTOSE OLIGOSACCHARIDE; GUM ARABIC; ICOSAPENTAENOIC ACID; LYPRINOL; MESALAZINE; NUTRACEUTICAL; OMEGA 3 FATTY ACID; OMEPRAZOLE; PHYTOESTROGEN; PHYTOSTEROL; PLANT EXTRACT; POLYPHENOL; POLYUNSATURATED FATTY ACID; PREBIOTIC AGENT; PROBIOTIC AGENT; RUTOSIDE; SELENIUM; ULTRA LEVURE; ULTRALEVURA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VETIVERIA ZINZANIOIDS EXTRACT; VSL3;

AEGLE; ANTIMICROBIAL ACTIVITY; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; CHILDHOOD DISEASE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COLORECTAL CANCER; CORIANDER; CROHN DISEASE; CURCUMA LONGA; CYPERUS; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENTERITIS; EPITHELIUM CELL; EVIDENCE BASED MEDICINE; FUNGEMIA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL INFECTION; HELICOBACTER INFECTION; HUMAN; ILEITIS; IMMUNOCOMPETENT CELL; INTESTINE EPITHELIUM; IRRITABLE COLON; MEDICINAL PLANT; NONHUMAN; NUTRITION; PANCREATITIS; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; ULCERATIVE COLITIS; VETIVERIA;

EID: 27744550164     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2005.06.009     Document Type: Review

References (93)

1. P.B. Eckburg E.M. Bik C.N. Bernstein E. Purdom L. Dethlefsen M. Sargent S.R. Gill K.E. Nelson D.A. Relman Diversity of the human intestinal microbial flora Science 308 2005 1635-1638
2. D.C. Montrose M.H. Floch Probiotics used in human studies J Clin Gastroenterol 39 2005 469-484
3. B.C. Foster J.T. Arnason C.J. Briggs Natural health products and drug disposition Annu Rev Pharmacol Toxicol 45 2005 203-226
4. S. Barnes J. Prasain Current progress in the use of traditional medicines and nutraceuticals Curr Opin Plant Biol 8 2005 324-328
5. J.I. Mechanick The rational use of dietary supplements and nutraceuticals in clinical medicine Mt Sinai J Med 72 2005 161-165
6. F. Lamine H. Eutamene J. Fioramonti L. Bueno V. Theodorou Colonic responses to Lactobacillus farciminis treatment in trinitrobenzene sulphonic acid-induced colitis in rats Scand J Gastroenterol 39 2004 1250-1258
7. R.B. Sartor Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: Antibiotics, probiotics, and prebiotics Gastroenterology 126 2004 1620-1633
8. Y. Cong A. Konrad N. Iqbal C.O. Elson Probiotics and immune regulation of inflammatory bowel diseases Curr Drug Targets Inflamm Allergy 2 2003 145-154
9. J.A. Pena S.Y. Li P.H. Wilson S.A. Thibodeau A.J. Szary J. Versalovic Genotypic and phenotypic studies of murine intestinal lactobacilli: species differences in mice with and without colitis Appl Environ Microbiol 70 2004 558-568
10. D. Rachmilewitz K. Katakura F. Karmeli T. Hayashi C. Reinus B. Rudensky S. Akira K. Takeda J. Lee K. Takabayashi et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis Gastroenterology 126 2004 520-528
11. M.T. Abreu M. Fukata M. Arditi TLR signaling in the gut in health and disease J Immunol 174 2005 4453-4460
12. E. Cario G. Gerken D.K. Podolsky Toll-like receptor 2 enhances ZO-1-associated intestinal epithelial barrier integrity via protein kinase C Gastroenterology 127 2004 224-238
13. J.M. Otte E. Cario D.K. Podolsky Mechanisms of cross hyporesponsiveness to Toll-like receptor bacterial ligands in intestinal epithelial cells Gastroenterology 126 2004 1054-1070
14. H. Jijon J. Backer H. Diaz H. Yeung D. Thiel C. McKaigney C. De Simone K. Madsen DNA from probiotic bacteria modulates murine and human epithelial and immune function Gastroenterology 126 2004 1358-1373
15. B. Sheil J. McCarthy L. O'Mahony M.W. Bennett P. Ryan J.J. Fitzgibbon B. Kiely J.K. Collins F. Shanahan Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis Gut 53 2004 694-700
16. Y.J. Surh Cancer chemoprevention with dietary phytochemicals Nat Rev Cancer 3 2003 768-780
17. Y.T. Jian G.F. Mai J.D. Wang Y.L. Zhang R.C. Luo Y.X. Fang Preventive and therapeutic effects of NF-kappaB inhibitor curcumin in rats colitis induced by trinitrobenzene sulfonic acid World J Gastroenterol 11 2005 1747-1752
18. W.S. Jeong I.W. Kim R. Hu A.N. Kong Modulatory properties of various natural chemopreventive agents on the activation of NF-kappaB signaling pathway Pharm Res 21 2004 661-670
19. G. Kang P.J. Kong Y.J. Yuh S.Y. Lim S.V. Yim W. Chun S.S. Kim Curcumin suppresses lipopolysaccharide-induced cyclooxygenase-2 expression by inhibiting activator protein 1 and nuclear factor kappab bindings in BV2 microglial cells J Pharmacol Sci 94 2004 325-328
20. H.H. Cui C.L. Chen J.D. Wang Y.J. Yang Y. Cun J.B. Wu Y.H. Liu H.L. Dan Y.T. Jian X.Q. Chen Effects of probiotic on intestinal mucosa of patients with ulcerative colitis World J Gastroenterol 10 2004 1521-1525
21. E.O. Petrof K. Kojima M.J. Ropeleski M.W. Musch Y. Tao C. De Simone E.B. Chang Probiotics inhibit nuclear factor-kappaB and induce heat shock proteins in colonic epithelial cells through proteasome inhibition Gastroenterology 127 2004 1474-1487
22. M. Candelli E.C. Nista E. Carloni G. Pignataro M.A. Zocco A. Cazzato C. Di Campli L. Fini G. Gasbarrini A. Gasbarrini Treatment of H. pylori infection: A review Curr Med Chem 12 2005 375-384
23. A. Ushiyama K. Tanaka Y. Aiba T. Shiba A. Takagi T. Mine Y. Koga Lactobacillus gasseri OLL2716 as a probiotic in clarithromycin-resistant Helicobacter pylori infection J Gastroenterol Hepatol 18 2003 986-991
24. A. Chatterjee T. Yasmin D. Bagchi S.J. Stohs The bactericidal effects of Lactobacillus acidophilus, garcinol and Protykin compared to clarithromycin, on Helicobacter pylori Mol Cell Biochem 243 2003 29-35
25. C.N. Wendakoon A.B. Thomson L. Ozimek Lack of therapeutic effect of a specially designed yogurt for the eradication of Helicobacter pylori infection Digestion 65 2002 16-20
26. F. Canducci A. Armuzzi F. Cremonini G. Cammarota F. Bartolozzi P. Pola G. Gasbarrini A. Gasbarrini A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates Aliment Pharmacol Ther 14 2000 1625-1629
27. L. Zhang J. Ma K. Pan V.L. Go J. Chen W.C. You Efficacy of cranberry juice on Helicobacter pylori infection: A double-blind, randomized placebo-controlled trial Helicobacter 10 2005 139-145
28. J.W. Fahey X. Haristoy P.M. Dolan T.W. Kensler I. Scholtus K.K. Stephenson P. Talalay A. Lozniewski Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors Proc Natl Acad Sci USA 99 2002 7610-7615
29. F. Cremonini S. Di Caro M. Covino A. Armuzzi M. Gabrielli L. Santarelli E.C. Nista G. Cammarota G. Gasbarrini A. Gasbarrini Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: A parallel group, triple blind, placebo-controlled study Am J Gastroenterol 97 2002 2744-2749
30. E.C. Nista M. Candelli F. Cremonini I.A. Cazzato M.A. Zocco F. Franceschi G. Cammarota G. Gasbarrini A. Gasbarrini Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial Aliment Pharmacol Ther 20 2004 1181-1188
31. E. Myllyluoma L. Veijola T. Ahlroos S. Tynkkynen E. Kankuri H. Vapaatalo H. Rautelin R. Korpela Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy - a placebo-controlled, double-blind randomized pilot study Aliment Pharmacol Ther 21 2005 1263-1272
32. J.D. Lambert J. Hong G.Y. Yang J. Liao C.S. Yang Inhibition of carcinogenesis by polyphenols: Evidence from laboratory investigations Am J Clin Nutr 81 2005 284S-291S
33. S.R. Volate D.M. Davenport S.J. Muga M.J. Wargovich Modulation of aberrant crypt foci and apoptosis by dietary herbal supplements (quercetin, curcumin, silymarin, ginseng and rutin) Carcinogenesis 26 2005 1450-1456
34. A. Chao M.J. Thun C.J. Connell M.L. McCullough E.J. Jacobs W.D. Flanders C. Rodriguez R. Sinha E.E. Calle Meat consumption and risk of colorectal cancer JAMA 293 2005 172-182
35. C.A. Jolly Diet manipulation and prevention of aging, cancer and autoimmune disease Curr Opin Clin Nutr Metab Care 8 2005 382-387
36. F. Borrelli R. Capasso A. Russo E. Ernst Systematic review: Green tea and gastrointestinal cancer risk Aliment Pharmacol Ther 19 2004 497-510
37. A. Nkondjock P. Ghadirian Associated nutritional risk of breast and colon cancers: A population-based case-control study in Montreal, Canada Cancer Lett 223 2005 85-91
38. S.A. Bingham N.E. Day R. Luben P. Ferrari N. Slimani T. Norat F. Clavel-Chapelon E. Kesse A. Nieters H. Boeing et al. Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): An observational study Lancet 361 2003 1496-1501
39. S.V. Malkov V.V. Markelov G.Y. Polozov L.I. Sobchuk N.G. Zakharova B.I. Barabanschikov A.Y. Kozhevnikov R.A. Vaphin M.V. Trushin Antitumor features of Bacillus oligonitrophilus KU-1 strain J Microbiol Immunol Infect 38 2005 96-104
40. J. Rafter Probiotics and colon cancer Best Pract Res Clin Gastroenterol 17 2003 849-859
41. J. Rafter Lactic acid bacteria and cancer: Mechanistic perspective Br J Nutr 88 Suppl 1 2002 S89-S94
42. J. Van Loo Y. Clune M. Bennett J.K. Collins The SYNCAN project: Goals, set-up, first results and settings of the human intervention study Br J Nutr 93 Suppl 1 2005 S91-S98
43. B.E. Lacy R.D. Lee Irritable bowel syndrome: A syndrome in evolution J Clin Gastroenterol 39 2005 S230-S242
44. R. Bundy A.F. Walker R.W. Middleton J. Booth Turmeric extract may improve irritable bowel syndrome symptomology in otherwise healthy adults: A pilot study J Altern Complement Med 10 2004 1015-1018
45. R. Bundy A.F. Walker R.W. Middleton G. Marakis J.C. Booth Artichoke leaf extract reduces symptoms of irritable bowel syndrome and improves quality of life in otherwise healthy volunteers suffering from concomitant dyspepsia: A subset analysis J Altern Complement Med 10 2004 667-669
46. H.J. Kim M. Camilleri S. McKinzie M.B. Lempke D.D. Burton G.M. Thomforde A.R. Zinsmeister A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome Aliment Pharmacol Ther 17 2003 895-904
47. L. O'Mahony J. McCarthy P. Kelly G. Hurley F. Luo K. Chen G.C. O'Sullivan B. Kiely J.K. Collins F. Shanahan Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles Gastroenterology 128 2005 541-551
48. G. Kecskes T. Belagyi A. Olah Early jejunal nutrition with combined pre- and probiotics in acute pancreatitis - prospective, randomized, double-blind investigations Magy Seb 56 2003 3-8
49. A. Olah T. Belagyi A. Issekutz M.E. Gamal S. Bengmark Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis Br J Surg 89 2002 1103-1107
50. S.J. Allen B. Okoko E. Martinez G. Gregorio L.F. Dans Probiotics for treating infectious diarrhoea Cochrane Database Syst Rev 2 2004 CD003048
51. C.M. Surawicz Probiotics, antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in humans Best Pract Res Clin Gastroenterol 17 2003 775-783
52. F. Cremonini S. Di Caro E.C. Nista F. Bartolozzi G. Capelli G. Gasbarrini A. Gasbarrini Meta-analysis: The effect of probiotic administration on antibiotic-associated diarrhoea Aliment Pharmacol Ther 16 2002 1461-1467
53. A.L. D'Souza C. Rajkumar J. Cooke C.J. Bulpitt Probiotics in prevention of antibiotic associated diarrhoea: Meta-analysis BMJ 324 2002 1361
54. L.V. McFarland C.M. Surawicz R.N. Greenberg R. Fekety G.W. Elmer K.A. Moyer S.A. Melcher K.E. Bowen J.L. Cox Z. Noorani et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease JAMA 271 1994 1913-1918
55. M. Wullt M.L. Hagslatt I. Odenholt Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: A double-blind, placebo-controlled trial Scand J Infect Dis 35 2003 365-367
56. R.N. Fedorak K.L. Madsen Probiotics and the management of inflammatory bowel disease Inflamm Bowel Dis 10 2004 286-299
57. B.J. Rembacken A.M. Snelling P.M. Hawkey D.M. Chalmers A.T. Axon Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial Lancet 354 1999 635-639
58. W. Kruis P. Fric J. Pokrotnieks M. Lukas B. Fixa M. Kascak M.A. Kamm J. Weismueller C. Beglinger M. Stolte et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine Gut 53 2004 1617-1623
59. W. Kruis E. Schutz P. Fric B. Fixa G. Judmaier M. Stolte Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis Aliment Pharmacol Ther 11 1997 853-858
60. E. Furrie S. Macfarlane A. Kennedy J.H. Cummings S.V. Walsh D.A. O'Neil G.T. Macfarlane Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: A randomised controlled pilot trial Gut 54 2005 242-249
61. R. Bibioloni G.W. Tannock K.L. Madsen P. Gionchetti M. Campieri C. De Simone R.B. Sartor VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis Am J Gastroenterol 100 2005 1539-1546
62. H. Ishikawa I. Akedo Y. Umesaki R. Tanaka A. Imaoka T. Otani Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis J Am Coll Nutr 22 2003 56-63
63. M. Guslandi P. Giollo P.A. Testoni A pilot trial of Saccharomyces boulardii in ulcerative colitis Eur J Gastroenterol Hepatol 15 2003 697-698
64. T.J. Borody E.F. Warren S. Leis R. Surace O. Ashman Treatment of ulcerative colitis using fecal bacteriotherapy J Clin Gastroenterol 37 2003 42-47
65. P. Gionchetti C. Amadini F. Rizzello A. Venturi V. Palmonari C. Morselli R. Romagnoli M. Campieri Probiotics - role in inflammatory bowel disease Dig Liver Dis 34 Suppl 2 2002 S58-S62
66. T. Mimura F. Rizzello U. Helwig G. Poggioli S. Schreiber I.C. Talbot R.J. Nicholls P. Gionchetti M. Campieri M.A. Kamm Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis Gut 53 2004 108-114
67. P. Gionchetti F. Rizzello U. Helwig A. Venturi K.M. Lammers P. Brigidi B. Vitali G. Poggioli M. Miglioli M. Campieri Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial Gastroenterology 124 2003 1202-1209
68. K.M. Lammers A. Vergopoulos N. Babel P. Gionchetti F. Rizzello C. Morselli E. Caramelli M. Fiorentino A. d'Errico H.D. Volk et al. Probiotic therapy in the prevention of pouchitis onset: Decreased interleukin-1beta, interleukin-8, and interferon-gamma gene expression Inflamm Bowel Dis 11 2005 447-454
69. K.O. Laake A. Bjorneklett G. Aamodt L. Aabakken M. Jacobsen A. Bakka M.H. Vatn Outcome of four weeks' intervention with probiotics on symptoms and endoscopic appearance after surgical reconstruction with a J-configurated ileal-pouch-anal-anastomosis in ulcerative colitis Scand J Gastroenterol 40 2005 43-51
70. J. Kuisma S. Mentula H. Jarvinen A. Kahri M. Saxelin M. Farkkila Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora Aliment Pharmacol Ther 17 2003 509-515
71. M. Schultz A. Timmer H.H. Herfarth R.B. Sartor J.A. Vanderhoof H.C. Rath Lactobacillus GG in inducing and maintaining remission of Crohn's disease BMC Gastroenterol 4 2004 5
72. C. Prantera M.L. Scribano G. Falasco A. Andreoli C. Luzi Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: A randomised controlled trial with Lactobacillus GG Gut 51 2002 405-409
73. H.A. Malchow Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 25 1997 653-658
74. A.H. Gilani A.J. Shah M.N. Ghayur K. Majeed Pharmacological basis for the use of turmeric in gastrointestinal and respiratory disorders Life Sci 76 2005 3089-3105
75. D. Tenikoff K.J. Murphy M. Le P.R. Howe G.S. Howarth Lyprinol (stabilised lipid extract of New Zealand green-lipped mussel): A potential preventative treatment modality for inflammatory bowel disease J Gastroenterol 40 2005 361-365
76. K.H. Kwon A. Murakami T. Tanaka H. Ohigashi Dietary rutin, but not its aglycone quercetin, ameliorates dextran sulfate sodium-induced experimental colitis in mice: Attenuation of pro-inflammatory gene expression Biochem Pharmacol 69 2005 395-406
77. A.G. Jagtap S.S. Shirke A.S. Phadke Effect of polyherbal formulation on experimental models of inflammatory bowel diseases J Ethnopharmacol 90 2004 195-204
78. C.V. Whiting P.W. Bland J.F. Tarlton Dietary n-3 polyunsaturated fatty acids reduce disease and colonic proinflammatory cytokines in a mouse model of colitis Inflamm Bowel Dis 11 2005 340-349
79. F.G. Campos D.L. Waitzberg A. Habr-Gama A.F. Logullo I.L. Noronha S. Jancar R.S. Torrinhas P. Furst Impact of parenteral n-3 fatty acids on experimental acute colitis Br J Nutr 87 Suppl 1 2002 S83-S88
80. A. Belluzzi Polyunsaturated fatty acids (n-3 PUFAs) and inflammatory bowel disease (IBD): Pathogenesis and treatment Eur Rev Med Pharmacol Sci 8 2004 225-229
81. A. Belluzzi C. Brignola M. Campieri A. Pera S. Boschi M. Miglioli Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease N Engl J Med 334 1996 1557-1560
82. J.E. Teitelbaum W. Allan Walker Review: The role of omega 3 fatty acids in intestinal inflammation J Nutr Biochem 12 2001 21-32
83. R.L. Koretz Immunonutrition: Can you be what you eat? Curr Opin Gastroenterol 19 2003 134-139
84. I. Dichi P. Frenhane J.B. Dichi C.R. Correa A.Y. Angeleli M.H. Bicudo M.A. Rodrigues C.R. Victoria R.C. Burini Comparison of omega-3 fatty acids and sulfasalazine in ulcerative colitis Nutrition 16 2000 87-90
85. D.S. Barbosa R. Cecchini M.Z. El Kadri M.A. Rodriguez R.C. Burini I. Dichi Decreased oxidative stress in patients with ulcerative colitis supplemented with fish oil omega-3 fatty acids Nutrition 19 2003 837-842
86. D.L. Seidner B.A. Lashner A. Brzezinski P.L. Banks J. Goldblum C. Fiocchi J. Katz G.R. Lichtenstein P.A. Anton L.Y. Kam et al. An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: A randomized, controlled trial Clin Gastroenterol Hepatol 3 2005 358-369
87. M. Arita M. Yoshida S. Hong E. Tjonahen J.N. Glickman N.A. Petasis R.S. Blumberg C.N. Serhan Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis Proc Natl Acad Sci USA 102 2005 7671-7676
88. S.P. Borriello W.P. Hammes W. Holzapfel P. Marteau J. Schrezenmeir M. Vaara V. Valtonen Safety of probiotics that contain lactobacilli or bifidobacteria Clin Infect Dis 36 2003 775-780
89. E. Isolauri P.V. Kirjavainen S. Salminen Probiotics: A role in the treatment of intestinal infection and inflammation? Gut 50 Suppl 3 2002 III54-III59
90. A.J. Riquelme M.A. Calvo A.M. Guzman M.S. Depix P. Garcia C. Perez M. Arrese J.A. Labarca Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients J Clin Gastroenterol 36 2003 41-43
91. M. Candelli E.C. Nista M. Nestola A. Armuzzi N.G. Silveri G. Gasbarrini A. Gasbarrini Saccharomyces cerevisiae-associated diarrhea in an immunocompetent patient with ulcerative colitis J Clin Gastroenterol 36 2003 39-40
92. J. Sykora K. Valeckova J. Amlerova K. Siala P. Dedek S. Watkins J. Varvarovska F. Stozicky P. Pazdiora J. Schwarz Effects of a specially designed fermented milk product containing probiotic Lactobacillus casei DN-114001 and the eradication of H. pylori in children: A prospective randomized double-blind study J Clin Gastroenterol 39 2005 692-698
93. P. Munoz E. Bouza M. Cuenca-Estella J. Eiros M. Perez M. Sanchez-Somolinos C. Rincon J. Hortal T. Pelaez Saccharomyces cerevisiae fungemia: An emerging infectious disease Clin Infect Dis 40 2005 1625-1634